Home > Pulmonology > ERS 2022 > Antifibrotic therapy may slow down FVC decline in RAILD

Antifibrotic therapy may slow down FVC decline in RAILD

Presented By
Prof. Ivan Rosas, Baylor College of Medicine, TX, USA
Conference
ERS 2022
Trial
Phase 2, TRAIL1
A phase 2 study examining pirfenidone in patients with rheumatoid arthritis associated interstitial lung disease (RAILD) did not meet its primary endpoint. Nonetheless, a trend was observed towards a beneficial effect for the agent under investigation, especially for patients with RAILD who displayed a pattern of usual interstitial pneumonia (UIP) on CT imaging. Rheumatoid arthritis (RA) is the most common connective tissue disease, with a prevalence of 0.75% in the USA [1]. In addition, interstitial lung disease (ILD) occurs in 19–63% of the patients with RA [1]. To target RAILD, Prof. Ivan Rosas (Baylor College of Medicine, TX, USA) and colleagues designed the phase 2 TRAIL1 study (NCT02808871), in which 123 patients with RAILD were randomised to the antifibrotic agent pirfenidone or placebo [2]. The primary endpoint was a decline in percent predicted FVC by 10% ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on